143 related articles for article (PubMed ID: 36889252)
1. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
Chen Z; Wang Q; Yan YY; Jin D; Wang Y; Zhang XX; Liu XH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305852. PubMed ID: 38258519
[TBL] [Abstract][Full Text] [Related]
3. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
Lee JC; Liu S; Wang Y; Liang Y; Jablons DM
Oncotarget; 2022 Nov; 13():1217-1236. PubMed ID: 36342456
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the Novel 1
Zhang XX; Xiao Y; Yan YY; Wang YM; Jiang H; Wu L; Shi JB; Liu XH
J Med Chem; 2022 Sep; 65(18):12095-12123. PubMed ID: 36068975
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy.
Yan YY; Zhang XX; Xiao Y; Shen XB; Jian YJ; Wang YM; She ZH; Liu MM; Liu XH
J Med Chem; 2022 Oct; 65(19):13216-13239. PubMed ID: 36126227
[TBL] [Abstract][Full Text] [Related]
9. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
Wang Y; Zhi Y; Jin Q; Lu S; Lin G; Yuan H; Yang T; Wang Z; Yao C; Ling J; Guo H; Li T; Jin J; Li B; Zhang L; Chen Y; Lu T
J Med Chem; 2018 Feb; 61(4):1499-1518. PubMed ID: 29357250
[TBL] [Abstract][Full Text] [Related]
11. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
13. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
Tang Y; Zheng Y; Hu X; Zhao H; Cui S
J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
[TBL] [Abstract][Full Text] [Related]
15. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
16. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
18. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
